Preferred Label : Navoximod;
NCIt synonyms : 5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-Fluoro-alpha-(trans-4-hydroxycyclohexyl)-,
(AlphaR,5S)-;
NCIt definition : An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential
immunomodulating and antineoplastic activities. Upon administration, navoximod targets
and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential
amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine
in tumor cells, this agent increases tryptophan levels, restores the proliferation
and activation of various immune cells, including dendritic cells (DCs), natural killer
(NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory
T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers,
may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor
cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important
role in immunosuppression. Tryptophan depletion is associated with immunosuppression
caused by T-cell suppression.;
UNII : 926SHL95NC;
InChIKey : YGACXVRLDHEXKY-WXRXAMBDSA-N;
CAS number : 1402837-78-8;
Molecule name : NLG-919; RO7077339-001; GDC-0919; RG6078;
NCI Metathesaurus CUI : CL471774;
Origin ID : C113793;
UMLS CUI : C4682396;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
